Entrada Therapeutics, Inc. · Brief

Next report

4 days

Nov 5 · before openest.Q3 FY26

Earnings

Expected move

No implied move.

Implied vs realized

8 reportsHistory

1 of 8≥ implied

avg implied: ±48.7%
avg realized: ±9.6%

Feb 27 '25±31.7%▼−0.33%×0.01

May 8 '25±53.3%▲+5.64%×0.11

Aug 6 '25±81.8%▲+2.06%×0.03

Q3 FY25±61.5%▲+0.14%×0.00

Jan 8 '26±42.8%▼−2.14%×0.05

Q1 FY26±38.0%▲+6.76%×0.18

May 7 '26±24.3%▼−57.27%×2.36

Q2 FY26±56.7%▼−2.49%×0.04

quarterimplied−85%0+85%realized×

Q2 FY26±56.7%▼−2.49%×0.04

May '26±24.3%▼−57.27%×2.36

Q1 FY26±38.0%▲+6.76%×0.18

Jan '26±42.8%▼−2.14%×0.05

Q3 FY25±61.5%▲+0.14%×0.00

Aug '25±81.8%▲+2.06%×0.03

2 older reports

May '25±53.3%▲+5.64%×0.11

Feb '25±31.7%▼−0.33%×0.01

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 5 report · est.

Bull2

3disclosed supplier and customer ties in SEC filingsSEC filings

128managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 4

7 of 8recent reports where the move came in under the options implied rangeEarnings history

0.01%of iShares Russell 2000 ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

AI captions · Sep 16 '26once per report · top 2 per case

Linked exposure

TRDA report session

Customers 1

VRTXVertex Pharmaceuticals×0.11

× = co-movement · max 500dSource: SEC filings · market data

Latest changes

30 daysAll changes

No changes.

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.